STOCK TITAN

Royalty Pharma Plc - RPRX STOCK NEWS

Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.

Royalty Pharma Plc (RPRX) drives biopharmaceutical innovation by funding therapies through strategic royalty acquisitions. This dedicated news hub provides investors with essential updates on the company's financial developments and industry impact.

Access real-time announcements including quarterly earnings, royalty agreement expansions, and regulatory milestones. Our curated feed helps stakeholders track RPRX's role in advancing treatments across oncology, immunology, and rare diseases.

Discover how Royalty Pharma's unique business model supports drug development while maintaining revenue stability. The page features verified updates on portfolio additions, strategic collaborations, and market analyses relevant to RPRX's position in healthcare finance.

Bookmark this page for streamlined access to Royalty Pharma's official communications and third-party analyses. Check regularly for insights into how the company continues shaping biopharma funding through calculated royalty investments.

Rhea-AI Summary
Royalty Pharma to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
Rhea-AI Summary
Royalty Pharma acquires synthetic royalty on Ferring's Adstiladrin gene therapy for up to $500 million. Ferring receives $300 million upfront and potential $200 million milestone payment. Royalty Pharma to acquire 5.1% royalty on US net sales, increasing to 8.0% upon milestone payment. Positive investment demonstrating confidence in Adstiladrin's potential. Adstiladrin aims to become new standard of care for high-risk bladder cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) reported strong financial results for Q2 2023, with net cash provided by operating activities of $608 million and Adjusted Cash Receipts of $545 million. They raised their 2023 guidance for Adjusted Cash Receipts to $2,900 to $2,975 million, reflecting a 6% to 10% underlying growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) to report Q2 2023 financial results on August 8, 2023. Conference call and webcast at 8:00 a.m. ET. Visit company website for details and replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) has announced a dividend payment of $0.20 per Class A ordinary share for the third quarter of 2023. The dividend will be paid on September 15, 2023, to shareholders of record as of August 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
dividends earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
-
Rhea-AI Summary

The board of directors of Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.20 per Class A ordinary share for the second quarter of 2023. This dividend will be distributed on June 15, 2023, to shareholders recorded by the close of business on May 19, 2023. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties, collaborating across the industry to fund innovation. Its portfolio includes royalties from over 35 commercial products like Vertex’s Trikafta and AbbVie’s Imbruvica, among others. The company plays a pivotal role in funding both late-stage clinical trials and acquiring existing royalties, supporting advancements in biopharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
dividends
Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) has announced its plan to report first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. A conference call, available via webcast, will be held at 8:00 a.m. ET on the same day.

The company, established in 1996, is recognized as the largest buyer of biopharmaceutical royalties, funding innovation across the industry. Royalty Pharma collaborates with various organizations, including academic institutions and pharmaceutical companies, and currently holds a portfolio of royalties on over 35 commercial products, which includes notable therapies such as Vertex’s Trikafta and Biogen’s Tysabri.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Royalty Pharma Plc

Nasdaq:RPRX

RPRX Rankings

RPRX Stock Data

14.13B
386.99M
9.83%
76.7%
3.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK